%0 Journal Article
%T How do we reach the goal of personalized medicine for neuroprotection in neonatal hypoxic-ischemic encephalopathy?
%A Zhou KQ
%A Dhillon SK
%A Bennet L
%A Davidson JO
%A Gunn AJ
%J Semin Perinatol
%V 48
%N 5
%D 2024 Aug 19
%M 38910063
%F 3.311
%R 10.1016/j.semperi.2024.151930
%X Therapeutic hypothermia is now standard of care for neonates with hypoxic-ischemic encephalopathy (HIE) in high income countries (HIC). Conversely, compelling trial evidence suggests that hypothermia is ineffective, and may be deleterious, in low- and middle-income countries (LMIC), likely reflecting the lower proportion of infants who had sentinel events at birth, suggesting that injury had advanced to a stage when hypothermia is no longer effective. Although hypothermia significantly reduced the risk of death and disability in HICs, many infants survived with disability and in principle may benefit from targeted add-on neuroprotective or neurorestorative therapies. The present review will assess biomarkers that could be used to personalize treatment for babies with HIE - to determine first whether an individual infant is likely to respond to hypothermia, and second, whether additional treatments may be beneficial.